Research programme: DGAT-1 inhibitors - Pfizer

Drug Profile

Research programme: DGAT-1 inhibitors - Pfizer

Alternative Names: BAY-744113; PF-0441560

Latest Information Update: 19 Apr 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bayer
  • Developer Pfizer
  • Class Antihyperlipidaemics; Obesity therapies
  • Mechanism of Action Diacylglycerol O acyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 03 Aug 2009 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
  • 07 Nov 2008 Pfizer exits research activities in the area of obesity
  • 30 Sep 2008 Discontinued - Preclinical for Obesity in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top